Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure

por Zaytsev, Daniil, Girshova, Larisa, Ivanov, Vladimir, Budaeva, Irina, Motorin, Dmitri, Badaev, Renat, Mirolubova, Julia, Grobovenko, Evgeni, Chitanava, Tamara, Zaykova, Ekaterina, Alexeeva, Julia, Zaritskey, Andrey
Publicado 2020

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

por Arcaini, Luca, Lamy, Thierry, Walewski, Jan, Belada, David, Mayer, Jiri, Radford, John, Jurczak, Wojciech, Morschhauser, Franck, Alexeeva, Julia, Rule, Simon, Cabeçadas, José, Campo, Elias, Pileri, Stefano A., Biyukov, Tsvetan, Patturajan, Meera, Casadebaig Bravo, Marie‐Laure, Trnĕný, Marek
Publicado 2017

Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience

por Chitanava, Tamara, Matvienko, Iuliia, Shuvaev, Vasily, Voloshin, Sergey, Martynkevich, Irina, Vlasova, Yulia, Efremova, Elizaveta, Mileeva, Ekaterina, Pirkhalo, Anna, Makarova, Taiana, Vlasik, Roman, Karyagina, Elena, Il`ina, Natalia, Medvedeva, Nadezhda, Dorofeeva, Natalia, Shneider, Tatiana, Siordiya, Nadia, Kulemina, Olga, Sbityakova, Evgenia, Lazorko, Natalia, Alexeeva, Julia, Motorin, Dmitrii, Morozova, Elena, Lomaia, Elza
Publicado 2023